Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 5,325 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Continuous Dose Clear all

Conditions: Anal, Colon, and Rectal Cancers, Colorectal Neoplasms, Colon/Rectal Cancer
Interventions: Vandetanib, Capecitabine, Oxaliplatin, Bevacizumab; Drug
Lead sponsor: Branimir Sikic; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV-1 Infection
Interventions: B/F/TAF, NRTIs, Third Agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 82
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more

Conditions: Pyruvate Kinase Deficiency
Interventions: Mitapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 12
States / cities: Phoenix, Arizona • Oakland, California • Atlanta, Georgia + 8 more

Conditions: Multiple Myeloma
Interventions: Velcade, Cyclophosphamide, Revlimid; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HNSCC
Interventions: Cesium-131, Pembrolizumab; Device · Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 19 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: Pompe Disease (Late-onset)
Interventions: Clenbuterol, Placebos; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: BIBW 2992; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 23
States / cities: Bakersfield, California • Beverly Hills, California • Mission Hills, California + 19 more

Conditions: Medulloblastoma, Childhood, Rhabdomyosarcoma
Interventions: LY2940680; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Months to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 4
States / cities: San Diego, California • Aurora, Colorado • Cincinnati, Ohio + 1 more

Conditions: Carcinoma, Neuroendocrine Tumors
Interventions: Cixutumumab, depot octreotide; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 6 more

Conditions: Sickle Cell Disease
Interventions: hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus, hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 25 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Graft Rejection
Interventions: Alemtuzumab, Anti-Thymocyte Globulin; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 65 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome, Tufted Angioma
Interventions: Vincristine, Sirolimus; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 31 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Palo Alto, California • Atlanta, Georgia • Baltimore, Maryland + 4 more

Conditions: Type 1 Diabetes
Interventions: Muscle Biopsy, Jell-O with Amino acids, Dextrose; Procedure · Other · Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: placebo, orelabrutinib; Other · Drug
Lead sponsor: Beijing InnoCare Pharma Tech Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Ormond Beach, Florida • Tampa, Florida • Northbrook, Illinois + 2 more

Conditions: Status Epilepticus
Interventions: lorazepam or diazepam; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 3 Months to 18 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 12
States / cities: Davis, California • Aurora, Colorado • Washington D.C., District of Columbia + 9 more

Conditions: RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Interventions: TAS0953/HM06; Drug
Lead sponsor: Taiho Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 9
States / cities: Orange, California • Stanford, California • Boston, Massachusetts + 5 more

Conditions: Breast Cancer Female
Interventions: SABR; Radiation
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Atrial Fibrillation
Interventions: Ranolazine, Matching placebo; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma

Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Interventions: rezatapopt, pembrolizumab; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 12 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Irvine, California • La Jolla, California • Los Angeles, California + 26 more

Conditions: PIK3CA-related Overgrowth Spectrum (PROS)
Interventions: Alpelisib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 0 Days to 100 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • St Louis, Missouri + 7 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Tolebrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Cullman, Alabama • Maitland, Florida • Tampa, Florida + 5 more

Conditions: Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelofibrosis, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Erdheim-Chester Disease, Refractory Follicular Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoplasmacytic Lymphoma, Refractory Myelodysplastic Syndrome, Refractory Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Refractory Waldenstrom Macroglobulinemia, Rosai-Dorfman-Destombes Disease, Primary Central Nervous System Lymphoma, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Erdheim-Chester Disease, Recurrent Fibroblastic Reticular Cell Sarcoma, Recurrent Histiocytic Sarcoma, Recurrent Interdigitating Dendritic Cell Sarcoma, Recurrent Rosai-Dorfman-Destombes Disease, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Fibroblastic Reticular Cell Sarcoma, Refractory Histiocytic Sarcoma, Refractory Interdigitating Dendritic Cell Sarcoma, Refractory Rosai-Dorfman-Destombes Disease
Interventions: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Survey Administration; Drug · Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Eosinophilic Esophagitis
Interventions: Dose; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 1 Year to 21 Years
Enrollment: 50 participants
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prediabetes, Type 2 Diabetes (T2DM)
Interventions: Vitamin D (Cholecalciferol ), Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 30 Years to 74 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Reduced Intensity Transplantation for Severe Sickle Cell Disease

Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors

Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus

A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis

Q702 for the Treatment of Patients With Hematologic Malignancies

Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children

Vitamin D and Type 2 Diabetes - Treat-To-Target